@article{APS10495,
author = {Chao Deng and Lin Zhao and Zhi Yang and Jia-jia Shang and Chang-yu Wang and Ming-zhi Shen and Shuai Jiang and Tian Li and Wen-cheng Di and Ying Chen and He Li and Ye-dong Cheng and Yang Yang},
title = {Targeting HMGB1 for the treatment of sepsis and sepsis- induced organ injury},
journal = {Acta Pharmacologica Sinica},
volume = {43},
number = {3},
year = {2022},
keywords = {},
abstract = {High mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that is present in almost all cells and regulates the activity of innate immune responses in both intracellular and extracellular settings. Current evidence suggests that HMGB1 plays a pivotal role in human pathological and pathophysiological processes such as the inflammatory response, immune reactions, cell migration, aging, and cell death. Sepsis is a systemic inflammatory response syndrome (SIRS) that occurs in hosts in response to microbial infections with a proven or suspected infectious etiology and is the leading cause of death in intensive care units worldwide, particularly in the aging population. Dysregulated systemic inflammation is a classic characteristic of sepsis, and suppression of HMGB1 may ameliorate inflammation and improve patient outcomes. Here, we focus on the latest breakthroughs regarding the roles of HMGB1 in sepsis and sepsis-related organ injury, the ways by which HMGB1 are released, and the signaling pathways and therapeutics associated with HMGB1. This review highlights recent advances related to HMGB1: the regulation of HMBG1 might be helpful for both basic research and drug development for the treatment of sepsis and sepsis-related organ injury.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10495}
}